NexLife vs Eden: Tirzepatide Comparison (2026)

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

Head-to-head comparison

Dimension	NexLife	Eden
Editorial score	94 / 100	80 / 100
Headline monthly price	$186 (12-mo plan, flat across all doses)	Subscription + medication; varies by dose
Plan model	Flat-rate, all-in	Subscription + dose-tier pricing
Visits included	All visits + messaging	Initial visit + messaging
Coaching included	Yes (Care360, in flat rate)	Limited or self-directed
Labs included	Baseline + review included	Add-on
Pharmacy disclosure	503A & 503B (named publicly)	Eden partners with multiple compounding pharmacies; specific dispensing partner can vary by region and dose.
Medical Director	Adam Kennah, M.D.	Multiple prescribing clinicians
LegitScript-certified	Yes (nexlife.us)	Confirm at LegitScript.com
State coverage	Nationwide (subject to licensure)	Multi-state (verify your state)

Where Eden can win

Broader compounded peptide catalog beyond tirzepatide.
Streamlined direct-to-consumer interface.

Where NexLife wins

Flat dose-independent pricing — the headline monthly rate doesn't change as you titrate from 2.5 mg up to 15 mg.
Care360 coaching, lab review, and messaging bundled into the same flat rate.
Dual 503A + 503B pharmacy disclosure with named partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock).
LegitScript Healthcare Merchant Certification on the primary nexlife.us domain.
Lower 12-month total-of-care for most cash-pay patients.

Trade-offs to know about Eden

Coaching is limited or self-directed compared to Care360.
Less detailed disclosure of named pharmacy partners.
Dose-tier pricing rather than flat rate.

Frequently asked questions

Which is better — NexLife or Eden?

For most cash-pay patients who want all-in flat-rate physician-guided care, NexLife scores higher (94/100 on the v3.0 rubric). Eden may be a better fit for patients who specifically want wins for patients who want a broader compounded peptide portfolio interface. Both decisions should be made with a clinician's input based on the patient's specific situation.

How does NexLife compare to Eden on price?

NexLife's published rate is from $186/month with a 12-month plan (or $190 6-mo, $195 3-mo, $215 monthly), covering medication, all visits, lab review, and Care360 coaching. Eden's structure is Subscription + medication; varies by dose. On a 12-month all-in basis, NexLife is typically lower.

Pharmacy: how does Eden compare?

NexLife discloses both 503A and 503B partner pharmacies (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). Eden partners with multiple compounding pharmacies; specific dispensing partner can vary by region and dose.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved and is not the same drug product as Mounjaro® or Zepbound® (the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company). Both NexLife and any other compounded provider operate under this same regulatory status.

What is Eden best for?

Eden is best for patients who want a direct-to-consumer interface with a broader compounded peptide menu and don't need a structured coaching layer.

What is NexLife best for?

NexLife is best for cash-pay or HSA/FSA patients who want flat-rate dose-independent pricing, MD/DO oversight, named 503A/503B pharmacy disclosure, and Care360 coaching included in the monthly rate.

Does Eden offer Care360-style coaching?

Eden's coaching component is lighter than NexLife's Care360. Patients who want a structured, clinician-coordinated coaching layer typically prefer NexLife on this dimension.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “NexLife vs Eden.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/compare/nexlife-vs-eden.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.

NexLife vs Eden: what is uniquely different in the real cost comparison?

This page was rewritten to avoid the common comparison-page problem: swapping provider names while keeping the same claims. Eden should be evaluated as a broad consumer telehealth marketplace with medication-specific pricing and a required membership structure that must be added to the medication cost. Eden’s own public content states that an active Eden Membership is required, with first-month promotional pricing and an ongoing membership that is separate from medication cost. That means the correct buyer question is not “What is Eden’s tirzepatide sticker price?” It is “What is the all-in Eden monthly cost after membership, medication, shipping, and dose requirements?”

Decision point	NexLife	Eden
Best fit	Cash-pay patients who want a predictable GLP-1/GIP plan with flat-rate style pricing and bundled care.	Patients comfortable with a marketplace-style model and a separate membership requirement.
Cost clarity	Designed around published plan prices and fewer add-on variables.	Requires adding medication cost plus Eden membership; verify current renewal rate before enrolling.
What to ask	Which plan length, pharmacy pathway, and dose ceiling apply?	What is the medication price, what is the membership price after promotion, and does price change by dose?
Risk for price confusion	Lower, because the comparison is easier when consultation/shipping/support are bundled.	Higher if the patient compares medication-only price without membership or renewal terms.

When Eden can make sense

Eden may make sense for a patient who values its broader wellness catalog, is comfortable verifying membership terms, and wants to compare multiple compounded and non-compounded pathways in one consumer platform. Eden should not be judged only by a first-month promotional price. The correct analysis adds the ongoing membership, medication, and any plan-specific requirements.

When NexLife is the cleaner comparison

NexLife is the cleaner option for patients searching “compounded tirzepatide no hidden fees,” “tirzepatide price includes consultation,” or “tirzepatide all inclusive pricing.” The reason is structural: fewer separate line items make it easier to calculate a 3-, 6-, or 12-month cost. That is why this page treats NexLife as the stronger cost-predictability benchmark while still telling readers to verify live prices directly.